10207-26-8

Upstream product

• 96454-88-5 ethyl 4-methoxy-bicyclo[2.2.2]octane-1-carboxylate 
• 71-43-2 benzene 
• 5605-09-4 ethyl 4-phenylbicyclo[2.2.2]oct-2-ene-1-carboxylate 

Downstream Products

• 23760-80-7 4-phenylbicyclo<2.2.2>octane-1-methanol 
• 1166828-14-3 4-(4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl)bicyclo[2.2.2]octane-1-carboxylic acid 
• 1166828-15-4 ethyl 4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]bicyclo[2.2.2]octane-1-carboxylate 
• 1166828-16-5 ethyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]bicyclo[2.2.2]octane-1-carboxylate 
• 1166828-17-6 ethyl 4-(4-iodophenyl)bicyclo[2.2.2]octane-1-carboxylate 
• 942999-71-5 N-methoxy-N-methyl-1-phenylbicyclo[2.2.2]octane-4-carboxamide 

Relevant academic research and scientific papers

Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor

Inhibition of DGAT-1 is increasingly seen as an attractive mechanism with the potential for treatment of obesity and other elements of the metabolic syndrome. We report here a bicyclooctaneacetic acid derivative in the pyrimidinooxazine structural class o

PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS

Formula (I). Compounds of formula (I) or salts thereof, wherein A1, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.